## Abstract In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average preโtax cost of bringing a new molecular entity to market. Their base case estimate, excluding postโmarketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 milli
โฆ LIBER โฆ
Marketing and drug costs: Who is laughing and crying?
โ Scribed by S. Claiborne Johnston; Stephen L. Hauser
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 40 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Drug development costs when financial ri
โ
John A. Vernon; Joseph H. Golec; Joseph A. Dimasi
๐
Article
๐
2009
๐
John Wiley and Sons
๐
English
โ 69 KB
Identifying who is at risk of drug-induc
โ
Shivakumar Chitturi; Geoffrey C. Farrell
๐
Article
๐
2011
๐
John Wiley and Sons
๐
English
โ 237 KB
In the classical form of alpha1-antitrypsin (AT) deficiency, a point mutation in AT alters the folding of a liver-derived secretory glycoprotein and renders it aggregation-prone. In addition to decreased serum concentrations of AT, the disorder is characterized by accumulation of the mutant alpha1-a
Acute and Chronic Toxicity of Veratrum V